Colorectal Cancer - Integrating the Latest Advances Into Clinical Practice: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco

This activity contains:

  • CME/CE-certified Audio Podcast

  • Downloadable Transcript

Release Date: 3/15/2016
Expiration Date: 3/14/2017
Estimated time to complete activity: 0.50 hours

Purpose
The goal of this activity is to provide clinicians with the latest clinical advances and emerging research in gastrointestinal cancers, as well as strategies to optimally integrate evolving evidence into clinical practice to improve the quality of care delivery.

Activity Overview
In 2015, there were an estimated 291,150 new cases of digestive system cancers in the United States, with an estimated 149,300 deaths (American Cancer Society, 2015). Having access to the most recent clinical advances in GI malignancies is crucial to making informed and timely treatment decisions. In this activity, an expert faculty member will highlight the most exciting and compelling data in colorectal cancer (CRC), and provide insights on how these clinical advances may be practice changing.

Target Audience

This activity is designed for medical oncologists, gastroenterologists, oncology nurses, advanced practice registered nurses and other healthcare professionals involved in the treatment and management of gastrointestinal cancers.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

•    Evaluate recent clinical trial data and emerging evidence of novel therapies for the treatment of gastrointestinal (GI) malignancies
•    Assess the implications of novel and emerging agents on clinical practice for the treatment of GI malignancies 
•    Implement appropriate individualized treatment plans for patients with GI malignancies based on recent clinical data
•    Provide appropriate care and counsel for patients and their families

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Attendance
Course opens: 
03/15/2016
Course expires: 
03/14/2017
Cost:
$0.00
Rating: 
0
Faculty 

J. Randolph Hecht, MD
Professor of Clinical Medicine
Carol and Saul Rosenzweig Chair for Cancer Therapies Development
Director of the UCLA GI Oncology Program
David Geffen School of Medicine at UCLA 
Los Angeles, California


Physician Continuing Medical Education
Accreditation Statement
The Postgraduate Institute for Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Credit Designation
This educational activity for 0.50 contact hour is provided by Postgraduate Institute for Medicine.

Designated for 0.1 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of FacultyReported Financial Relationship
J. Randolph Hecht, MDConsulting fee: Amgen, Inc.; Boston Biomedical; Genentech, Inc.


The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following AXIS planners and managers, Linda Gracie-King, MS; Ronald Viggiani, MD; Isabelle Vacher; Deborah Middleton, MS; and Jocelyn Timko, BS, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period 3/15/2016, through, 3/14/2017, participants must read the learning objectives and faculty disclosures and study the educational activity.  

Upon successfully completing the post-test with a score of 66% or better and the activity evaluation, your certificate will be made available immediately.

MEDIA SYSTEM REQUIREMENTS
PC
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v7.0.1.9 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader* 
MAC
MAC OS 10.2.8
Flash Player Plugin (v7.0.1.9 or greater)
Safari
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh. 


Safeguards Against Commercial Bias 
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education’s content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:

     1. Fair balance                                         
         a. Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
         b. No single product or service is overrepresented when other equal competing products or services are available for inclusion
     2. Scientific objectivity of studies mentioned in the materials or used as the basis for content
     3. Appropriateness of patient care recommendations made to learners

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This activity is supported by educational grants from Novartis Pharmaceuticals, Taiho Oncology, Inc., and Lilly.  For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

There is no fee for this educational activity.

Jointly provided by

To contact PIM please visit: www.pimed.com

AXIS 1410 Colorectal

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
  • 0.50 Attendance

Accreditation Period

Course opens: 
03/15/2016
Course expires: 
03/14/2017

Price

Cost:
$0.00
Please login or register to take this course.